HUP0401586A2 - Antibacterial agent - Google Patents
Antibacterial agentInfo
- Publication number
- HUP0401586A2 HUP0401586A2 HU0401586A HUP0401586A HUP0401586A2 HU P0401586 A2 HUP0401586 A2 HU P0401586A2 HU 0401586 A HU0401586 A HU 0401586A HU P0401586 A HUP0401586 A HU P0401586A HU P0401586 A2 HUP0401586 A2 HU P0401586A2
- Authority
- HU
- Hungary
- Prior art keywords
- bacterial
- gram
- antibacterial agent
- antibacterial
- mycoplasmas
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 abstract 2
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001430197 Mollicutes Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004292 cytoskeleton Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A találmány tárgyát az EF-Tu bakteriális transzlációs faktorhoz kötődőanyagok felhasználása képezi, sejtváz felépülésének megakadályozásárabaktériumsejtekben. A találmány tárgyát képezik továbbá olyanbaktériumellenes szerek, amelyek bakteriális EF-Tu fehérje 2. és/vagy3. doménje aminosav-szekvenciájának - előnyösen 4-20 aminosavból álló- részleteit tartalmazzák. A Gram-pozitív, Gram-negatív baktériumok,valamint mikoplazmák ellen hatásos baktériumellenes szertgyógyszerkészítményként, adott esetben gyógyszerészetileg szokásoshordozóanyagokkal, hígítószerekkel és/vagy segédanyagokkal együttformulázzák. ÓThe subject of the invention is the use of substances that bind to the bacterial translation factor EF-Tu to prevent the formation of a cytoskeleton in bacterial cells. The invention also relates to antibacterial agents that target bacterial EF-Tu protein 2 and/or 3. contain details of the amino acid sequence of its domain - preferably consisting of 4-20 amino acids. Effective against Gram-positive and Gram-negative bacteria, as well as mycoplasmas, it is formulated as an antibacterial medicinal product, where appropriate, together with pharmaceutical standard carriers, diluents and/or auxiliaries. HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10121145 | 2001-04-30 | ||
| DE10129870A DE10129870A1 (en) | 2001-04-30 | 2001-06-21 | Antibacterial |
| PCT/EP2002/004410 WO2002087554A2 (en) | 2001-04-30 | 2002-04-22 | Ef-tu binding agent as antibacterial agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401586A2 true HUP0401586A2 (en) | 2004-11-29 |
| HUP0401586A3 HUP0401586A3 (en) | 2005-06-28 |
Family
ID=26009202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401586A HUP0401586A3 (en) | 2001-04-30 | 2002-04-22 | Antibacterial agent |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1397157A2 (en) |
| JP (1) | JP2004534016A (en) |
| CN (1) | CN1298739C (en) |
| AU (1) | AU2002302555B2 (en) |
| BG (1) | BG108399A (en) |
| BR (1) | BR0209282A (en) |
| CA (1) | CA2445995A1 (en) |
| CZ (1) | CZ20033271A3 (en) |
| EE (1) | EE200300530A (en) |
| HU (1) | HUP0401586A3 (en) |
| IL (1) | IL158627A0 (en) |
| MX (1) | MXPA03009954A (en) |
| NZ (1) | NZ529662A (en) |
| PL (1) | PL366836A1 (en) |
| RU (1) | RU2003134636A (en) |
| SK (1) | SK14792003A3 (en) |
| WO (1) | WO2002087554A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10229645A1 (en) * | 2002-07-02 | 2004-05-19 | Kuchenreuther, Ulrich, Dr. | Cell disruption of bacteria |
| PT2459176T (en) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| CN105218668B (en) * | 2015-10-30 | 2020-03-24 | 山东农业大学 | EF-Tu protein monoclonal antibody MAb of Malta brucellosis as well as preparation method and application thereof |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0466251A1 (en) * | 1990-07-10 | 1992-01-15 | Gist-Brocades N.V. | Elfamycin-resistant mutants |
| ES2275336T3 (en) * | 1998-01-23 | 2007-06-01 | Biomerieux B.V. | EF-TU mRNA TO DETERMINE THE VIABILITY OF BACTERIA. |
| US6451556B1 (en) * | 1998-12-21 | 2002-09-17 | Smithkline Beecham Corporation | EF-Tu |
-
2002
- 2002-04-22 CN CNB028102185A patent/CN1298739C/en not_active Expired - Fee Related
- 2002-04-22 PL PL02366836A patent/PL366836A1/en unknown
- 2002-04-22 BR BR0209282-4A patent/BR0209282A/en not_active Application Discontinuation
- 2002-04-22 MX MXPA03009954A patent/MXPA03009954A/en unknown
- 2002-04-22 EE EEP200300530A patent/EE200300530A/en unknown
- 2002-04-22 EP EP02730187A patent/EP1397157A2/en not_active Withdrawn
- 2002-04-22 AU AU2002302555A patent/AU2002302555B2/en not_active Ceased
- 2002-04-22 IL IL15862702A patent/IL158627A0/en unknown
- 2002-04-22 CA CA002445995A patent/CA2445995A1/en not_active Abandoned
- 2002-04-22 CZ CZ20033271A patent/CZ20033271A3/en unknown
- 2002-04-22 JP JP2002584900A patent/JP2004534016A/en active Pending
- 2002-04-22 SK SK1479-2003A patent/SK14792003A3/en unknown
- 2002-04-22 HU HU0401586A patent/HUP0401586A3/en unknown
- 2002-04-22 NZ NZ529662A patent/NZ529662A/en unknown
- 2002-04-22 RU RU2003134636/13A patent/RU2003134636A/en unknown
- 2002-04-22 WO PCT/EP2002/004410 patent/WO2002087554A2/en not_active Application Discontinuation
-
2003
- 2003-12-01 BG BG108399A patent/BG108399A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002302555B2 (en) | 2007-08-23 |
| CZ20033271A3 (en) | 2004-06-16 |
| WO2002087554B1 (en) | 2005-01-27 |
| BG108399A (en) | 2004-08-31 |
| WO2002087554A2 (en) | 2002-11-07 |
| CN1298739C (en) | 2007-02-07 |
| EP1397157A2 (en) | 2004-03-17 |
| CN1518455A (en) | 2004-08-04 |
| HUP0401586A3 (en) | 2005-06-28 |
| WO2002087554A3 (en) | 2003-01-30 |
| PL366836A1 (en) | 2005-02-07 |
| EE200300530A (en) | 2004-04-15 |
| IL158627A0 (en) | 2004-05-12 |
| JP2004534016A (en) | 2004-11-11 |
| BR0209282A (en) | 2004-07-27 |
| MXPA03009954A (en) | 2005-07-25 |
| SK14792003A3 (en) | 2004-07-07 |
| NZ529662A (en) | 2006-08-31 |
| RU2003134636A (en) | 2005-04-20 |
| CA2445995A1 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT759774E (en) | METHOD FOR THE TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTIONS BY ADMINISTRATION OF A PERMEABILITY INDUCTIVE BACTERICIDE PROTEIN (BIP) PRODUCT AND ANTIBIOTIC | |
| ATE427116T1 (en) | TREATMENT OF BACTERIAL INFECTIONS | |
| DK0754050T3 (en) | Anti-gram-positive bacterial methods and materials | |
| ATE247972T1 (en) | PULMONARY DELIVERY OF PROTONATED/ACIDIFIED NUCLEIC ACID | |
| DE69331953D1 (en) | ANTIMICROBIAL POLYPEPTIDES | |
| NO951198L (en) | Lipopeptide derivatives, process for their preparation and use of the derivatives | |
| RU93004457A (en) | 1-CARBES- (1-DETIA) -CEFITS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION | |
| HUP9904308A2 (en) | Use of mupirocin for manufacture of a medicament for the treatment of bacterial infections associated with colonisation by pathogenic organisms at the nasopharynx | |
| DE69224069D1 (en) | PHARMACEUTICAL COMBINATION PRODUCT CONTAINING A URICOSURIC AGENT AND AN EXCITATORIC AMINO ACID ANTAGONIST | |
| EP1019084A4 (en) | Novel antimicrobial polypeptide and methods of use | |
| EA201991233A1 (en) | NEW ENDOLYSINE | |
| CA3010564A1 (en) | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition | |
| HUP0401586A2 (en) | Antibacterial agent | |
| DE60034879T8 (en) | lantibiotic | |
| NZ510153A (en) | Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals | |
| Li et al. | Characterization of antimicrobial peptides isolated from the processing by-products of African Catfish Clarias gariepinus | |
| ATE356147T1 (en) | ANTIBODIES FOR PREVENTING AND TREATING E. COLI AEEC DISEASES | |
| WO2005021575A3 (en) | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties | |
| BR0108096A (en) | Method for maintaining or improving mucin synthesis | |
| DE69838615D1 (en) | ppGpp-Synthetase and expression systems for the improved production of proteins | |
| WO2005005469A3 (en) | Novel purified polypeptides from staphylococcus aureus | |
| WO2003025004A3 (en) | Purified bacterial polypeptides involved in nucleic acid processing | |
| BR0007491A (en) | Use of 3-isoxazolidinones and hydroxylamic acids to treat infections | |
| WO2003035858A3 (en) | Bacterial polypeptides involved in nucleic acid processing | |
| WO2003053959A8 (en) | Heterocyclylamino carbonyluracils |